|
|
The Independent Clinical Lab Bulletin
The Clinical Current
Innovation, regulation, and strategic trends in molecular testing & remnant sample research
August 2026 | ENDO Lab & Medical Systems
|
 |
|
The laboratory market is sending two messages at once. Near-term operating discipline matters more than ever, while the long-term value of high-quality specimens and structured clinical data continues to rise. This issue highlights five developments that deserve attention from high-complexity laboratories and research partners.
01 CMS Puts 2027 CLFS Reductions Back on the Planning Calendar
CMS proposed rule issued July 14, 2026
CMS has proposed regulatory changes to implement the Consolidated Appropriations Act, 2026 amendments affecting the Clinical Laboratory Fee Schedule. The changes address data collection, reporting, and the phase-in of payment reductions for clinical diagnostic laboratory tests.
The 2026 reporting period ended July 31. Beginning in 2027, payment reductions tied to private-payor rate data may reach as much as 15 percent per year through 2029.
Why this matters: Laboratories should model profitability at the assay and panel level now. Medical necessity, coding discipline, utilization, reagent cost, and workflow efficiency will all matter when reimbursement tightens. Waiting for final rates may leave too little time to adjust a test menu or operating model.
LET'S TALKContact John Castelino or Jason Heffner to discuss how this could affect your lab: John or Jason.
Source: CMS CY 2027 Physician Fee Schedule Proposed Rule
02 Cyclospora Surge Highlights the Need for Flexible Molecular Capacity
CDC surveillance updated August 11, 2026
CDC reported 13,895 laboratory-confirmed, domestically acquired cyclosporiasis cases from May 1 through August 10, compared with 1,180 reported during the comparable 2025 seasonal period. CDC also reported 740 hospitalizations and said thousands of additional reports still require investigation.
Cyclospora can be difficult to detect, often requires specifically requested testing, and is not included in every routine stool workup. CDC is also working with partners to develop and validate molecular fingerprinting tools for outbreak investigation.
Why this matters: High-complexity laboratories with adaptable gastrointestinal molecular workflows can play an important role in case confirmation, reporting, and outbreak response. Labs should know which organisms are included in each panel, when targeted testing is needed, and whether current capacity can absorb a sudden regional surge.
LET'S TALKContact John Castelino to discuss infectious-disease panel capabilities and testing strategy: [email protected].
Source: CDC Cyclosporiasis Surveillance
03 $36.4 Million Genetic-Testing Settlement Raises the Compliance Stakes
DOJ announcement dated July 30, 2026
A Texas laboratory, its former CEO, and a Florida businessman agreed to pay a combined $36.4 million to resolve allegations involving kickbacks and medically unnecessary genetic testing. The government alleged improper marketer payments, unbundled billing, false telemedicine orders, and false claims.
The laboratory also entered a five-year Corporate Integrity Agreement requiring a stronger compliance program, training, auditing, accountability, and review of referral-source arrangements. The settlement resolves allegations and is not a finding of liability.
Why this matters: Every laboratory should be able to explain why a test was ordered, how referrals and marketing relationships are structured, how codes were selected, and how documentation supports medical necessity. Growth that cannot withstand an audit is not durable growth.
LET'S TALKContact Jason Heffner to discuss building a disciplined and sustainable molecular testing relationship: [email protected].
Source: U.S. Department of Justice settlement announcement
04 NIH's All of Us Dataset Shows Where Precision Research Is Heading
NIH announcement dated June 30, 2026
NIH released data from more than 747,000 All of Us participants, creating what the agency describes as the world's largest integrated genomics and electronic health record database. The release includes more than 535,000 whole-genome sequences linked to nearly 482,000 electronic health records.
The program has also entered a multiomics phase, adding proteomics, RNA sequencing, structural-variant, long-read sequencing, physical-measurement, survey, and environmental data. More than 86 percent of participants represented in the release come from groups historically underrepresented in biomedical research.
Why this matters: Research value increasingly comes from the connection between a specimen and reliable context. For independent labs, this reinforces the importance of consistent de-identification, structured data fields, pre-analytical documentation, and specimen traceability.
LET'S TALKContact David Curley to explore a compliant remnant-specimen and data program: [email protected].
Source: NIH All of Us data release
05 Circular RNA Blood Markers May Help Predict Alzheimer's Symptom Onset
NIH-funded study highlighted July 1, 2026
NIH highlighted research involving blood data from more than 1,200 people across multiple cohorts. Investigators identified 34 circular RNAs associated with Alzheimer's disease and found that the combined marker model performed similarly to pTau217 for identifying Alzheimer's pathology.
The circular RNA model was more informative for predicting progression to symptomatic disease. In the study, marker levels appeared to diverge from normal roughly two to four years before symptom onset, although further validation is needed before clinical use.
Why this matters: Blood-based biomarkers are expanding the research questions laboratories can support, from diagnosis to disease staging, trial enrollment, and treatment-response monitoring. Labs with well-characterized plasma or whole-blood remnants and usable neurological data may become increasingly valuable research partners.
LET'S TALKContact David Curley to discuss neurological specimens and biomarker-research opportunities: [email protected].
Source: NIH Alzheimer's biomarker research summary
|
Industry Events to Watch
| EVENT | WHY IT MATTERS |
|---|
Next Generation Dx Summit
August 24–26 | Washington, DC | Diagnostic development, liquid biopsy, biomarkers, reimbursement, commercialization, and partnering. |
CAP26 Annual Meeting
October 3–6 | Las Vegas | Pathology, laboratory leadership, diagnostic innovation, quality, and operations. |
ASHG 2026 Annual Meeting
October 20–24 | Montréal | Human genetics, genomics, multiomics, population research, and discovery platforms. |
AMP 2026 Annual Meeting & Expo
November 10–14 | Seattle | Molecular pathology, oncology, infectious disease, clinical genomics, and informatics. |
ASCP & CAP-ACP Annual Meeting
November 17–20 | Montréal | Education and collaboration across pathology and the full clinical laboratory team. |
If you are attending any of these events, let's coordinate time to connect. Contact David Curley at [email protected].
|
Quick Thought
The most valuable laboratory asset may no longer be the test result by itself. It is the combination of a defensible result, a traceable specimen, and structured data that can be used responsibly. Labs that build that discipline now can protect reimbursement today while opening research opportunities tomorrow.
Final Thought
The pressure on laboratories is real: tighter reimbursement, sharper enforcement, new outbreaks, and rapidly changing technology. But the opportunity is equally real. Independent high-complexity labs can remain competitive by understanding test-level economics, maintaining disciplined compliance, adapting their molecular capabilities, and treating eligible remnant specimens as research-ready assets rather than waste.
If any of these trends intersect with your current initiatives, ENDO would welcome the opportunity to learn more about your laboratory and explore where we may be able to help. Contact Dave, Jason, or John to start the conversation.
|
|
|
